WeTrials
Recruiting

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors

What is this study?

This study is testing an investigational medication called TOS-358 for adults with a specific type of advanced breast cancer. Researchers want to find the safest and most effective dose of this medicine, both by itself and when combined with standard breast cancer treatments.

Who can participate?

You may be able to join if you are 18 or older, have hormone receptor-positive, HER2-negative breast cancer that has spread, and your tumor has a specific genetic change called a PIK3CA mutation. People with poorly controlled diabetes or active cancer in the brain or spinal cord cannot participate.

What will happen?

Participants will take the study medication orally, either once or twice a day, and may also receive standard breast cancer therapies depending on the study phase. Your health and safety will be closely monitored by the medical team throughout the trial.

Where and when?

This study is currently recruiting participants at medical centers in cities such as Chicago, Illinois, and Boston, Massachusetts.

Key Points
  • 1Tests a new targeted cancer medication called TOS-358.
  • 2Open to adults with specific genetic mutations in their breast cancer.
  • 3Currently recruiting patients and actively monitoring safety and effectiveness.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
HR+/HER2-negative Breast Cancer

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.